SOURCE: Radient Pharmaceuticals Corporation

November 30, 2009 15:00 ET

Radient Pharmaceuticals Reschedules Third Quarter 2009 Earnings Conference Call to Thursday December 3, 2009

TUSTIN, CA--(Marketwire - November 30, 2009) - Radient Pharmaceuticals Corporation (NYSE Amex: RPC), a US-based pharmaceutical company that specializes in In Vitro Diagnostic (IVD) cancer tests and cell-renewing skin care products, today announced that, due to requirements related to the Company's registered direct finance offering and shareholder requests, it has changed the date of its previously announced third quarter earnings results conference call from Monday, November 30, 2009 to Thursday, December 3, 2009.

The rescheduled Q309 earnings conference call, hosted by Radient Pharmaceuticals senior management, will be held on Thursday, December 3, 2009 at 1:30 p.m. PST/4:30 p.m. EST to discuss the financial results of the Company for its third quarter ended September 30, 2009. Domestic listeners may access the call by dialing 1.877.360.1705 or 1.706.902.3245 for international callers with both US and international callers using access code 43792236. An audio cast will also be available through the Company's corporate website at The replay of the call will be available through December 10, 2009. For additional information on Radient Pharmaceuticals and its portfolio of products visit the Company's corporate website at

About Radient Pharmaceuticals:

Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is an integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, and premium skin care products.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Contact Information

  • AMDL Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    Email Contact
    (Tel: ) 206.310.5323